To Study Effect of Cilnidipine Inhypertensive Patients with Comorbid Diabetes Mellitus in Tertiary Care Hospital in Uttar Pradesh

Background: Hypertension is a widespread public health problem and a major risk factor. Angiotensin - converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are first line of treatment in case of albuminuria. When the patients do not respond to ARB monotherapy, diuretics or non - dihydropyridine calcium channel blockers (CCBs) are the second line of drugs. The dihydropyridie CCB, amlodipine is a widely used drug but has no renoprotective property. Cilnidipine, a new Type of CCB which can inhibit L - Type calcium channels but also N - Type calcium channels having anti proteinuric effect. Objective: The objective of the study was to evaluate the effect of cilnidipine by estimating urinary albumin and creatinine levels in hypertension (HTN) with Type 2 diabetes mellitus (DM). Methods: This was a single - center, prospective, open - labeled, randomized study. A total of 80 patients of either gender aged between 30 and 60 with mild - to - moderate HTN with comorbid Type 2 DM visiting OPD at SIMS, Hapur, were included in the study. Urine albumin and serum creatinine were measured at day 1 and end of 6 months. Blood pressure (BP) was measured in all visits. The drug cilnidipine at a dose of 10?20 mg oral was given and the corresponding improvement in the levels of urine albumin and other parameters was identified. Results: There was a significant reduction in the mean SBP and also in DBP in the first, second and third visit. The mean heart rate at visit zero was 77.11 ? 5.04. At the end of 6 months of treatment, there was significant reduction to 71.02 ? 3.04. There was a significant reduction in microalbuminuria from 67.24 ? 8.64 to 37.14 ? 8.24. There was no change in creatinine levels. Conclusion: The study reveals that the drug cilnidipine is safe and effective in reducing the microalbuminuria and also effectively reduces BP in hypertensive patients. Hence, the drug cilnidipine can be safely administered to the patient with diabetes and HTN.